

ANTIMICROBIAL SUSCEPTIBILITY PROFILE - Percent Susceptible

UTMB INPATIENT GRAM NEGATIVE BACILLI		Amikacin	Ampicillin	Amp/Subactam	Aztreonam	Cefazolin	Cefepime	Cefotaxime	Ceftazidime ¹	Cefuroxime (oral)	Cefuroxime sodium	Gentamicin	Imipenem	Levofloxacin	Nitrofurantoin ²	Piper/ tazobact	Ticar/ clav acid	Tobramycin	Trimeth/sulfa
Acinetobacter baumannii (n = 84)	70	-	22	-	-	20	11	20	-	-	28	29	22	-	21	40	64	34	
Citrobacter(versus) koseri (n = 31)	100	-	74	-	87	100	100	100	73	73	100	100	100	100	96	93	100	93	
Citrobacter freundii(n =20)	100	-	10	-	15	100	85	85	20	20	80	100	80	85	80	95	95	40	
Enterobacter aerogenes (n =41)	100	-	12	-	7	100	85	82	21	24	100	97	92	36	80	78	97	97	
Enterobacter cloacae (n = 90)	98	-	8	-	3	96	77	77	6	7	87	100	86	36	68	74	88	80	
Escherichia coli (n=921)	99	40	45	-	57	97	97	96	85	89	86	99	65	98	90	74	94	59	
Klebsiella oxytoca (n=32)	100	-	75	-	78	96	96	100	87	87	96	100	93	87	93	93	96	84	
Klebsiella pneumoniae (n = 252)	100	-	81	-	86	96	96	94	78	82	97	100	91	58	94	90	98	89	
Morganella morganii (n=18)	100	-	16	-	5	100	94	94	5	5	83	94	88	22	94	100	100	72	
Proteus mirabilis (n=116)	100	75	92	-	78	99	100	99	100	100	93	100	84	2	100	100	94	75	
Pseudomonas aeruginosa (n=354)	88	-	-	59	-	88	-	83	-	-	80	80	56	-	86	-	85	-	
Serratia marcescens (n=43)	100	-	16	-	-	97	97	97	-	-	97	100	97	-	97	95	100	97	
Stenotrophomonas maltophilia (n=49)	-	-	-	-	-	-	-	-	-	-	-	-	-	72	-	53	-	100	
Haemophilus influenzae (n=50)	-	82 ³	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Moraxella catarrhalis (n=20)	-	5 ³	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	

UTMB INPATIENT GRAM POSITIVE COCCI		Ampicillin	Cefotaxime CSF ⁴	Cefotaxime Non-CSF	Cefuroxime sodium	Clindamycin	Erythromycin	Levofloxacin ⁹	Linezolid	Oxacillin	Penicillin	Rifampin ¹⁰	Tetracycline	Trimeth/sulfa	Vancocycin
Enterococcus group D (n = 330)	90	-	-	-	-	-	-	-	100	-	-	-	-	-	93
Enterococcus faecalis (n = 39)	100	-	-	-	-	-	-	-	100	-	-	-	-	-	79
Enterococcus faecium (n = 37)	18	-	-	-	-	-	-	-	97	-	-	-	-	-	23
Staphylococcus aureus (n =937)	-	-	-	-	78	29	56	100	41	-	99	93	97	100	
Staphylococcus spp.coag neg (n = 223)	-	-	-	-	60	28	38	100	32	-	91	80	49	100	
Streptococcus pneumoniae (n = 59)	-	76 ⁵	82 ⁶	55	84	66	98	-	-	57 ⁷	-	-	-	100	
Streptococcus group A (n = 37)	-	-	-	-	58	66	-	-	-	100	-	-	-	-	
Streptococcus group B (n = 12)	-	-	-	-	60	40	-	-	-	100	-	-	-	-	
Viridans Streptococcus (n = 12)	-	-	-	-	-	-	-	-	-	66 ⁸	-	-	-	-	

n = number of isolates 7/2007- 6/2008. Not all isolates were tested with each antibiotic.

- = not tested, testing inappropriate, or testing not necessary

1-cefepime has replaced ceftazidime for adult use

2- Urine isolates only

3- Based on β lactamase testing

4- Interpretive criteria for susceptibility of *S. pneumoniae* to cephalosporins are different for CSF and non-CSF isolates

9-*Staphylococcus* spp.may develop resistance during prolonged therapy with quinolones.

10- RX: Rifampin should not be used alone for chemotherapy.

5-5% intermediate; 17% resistant

6-2% intermediate, 14% resistant

7- 22% intermediate; 19% resistant

8-25% intermediate; 8% resistant